[D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.

Leinung MC, Grasso P

Regulatory peptides5 Sept 2012Cited by 16 (Europe PMC)

PMID22960403DOI10.1016/j.regpep.2012.08.006PepBankPUB-22960403

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

10 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, oral exenatide reduced body weight gain versus DDM alone.
In plain wordsIn mice, oral exenatide reduced weight gain compared with DDM alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight gain
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Comparator
DDM alone
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · oral gavage · 14 daysAs given in this study (mouse).
Measurements
Weight gain
13.9%
exenatide
Weight gain
19.7%
DDM alone
Source sentences
Summary
Mice given DDM alone for 14 days were 19.7% heavier than they were at the beginning of the study, while oral delivery of exenatide or [D-Leu-4]-OB3 in DDM reduced body weight gain to only 13.9% and 11.5%, respectively, of initial body weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
Report a problemFND-2296040301
02AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, pramlintide acetate reduced weight gain versus Intravail-treated controls.
In plain wordsIn mice, pramlintide acetate reduced weight gain compared with Intravail-treated controls.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight gain
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Comparator
Intravail-treated control
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · oral gavage · 14 daysAs given in this study (mouse).
Measurements
Weight gain
26.8%
pramlintide acetate
Weight gain
38.2%
control
Source sentences
Summary
In another study, Intravail® treated control mice gained 38.2% of their initial body weight, while mice receiving pramlintide acetate or [D-Leu-4]-OB3 were only 26.8% and 25.4% heavier, respectively, at the end of the study,
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
Report a problemFND-2296040303
03AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, exenatide alone reduced food intake.
In plain wordsIn mice, exenatide alone reduced food intake.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFood intake
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · oral gavage · 14 daysAs given in this study (mouse).
Source sentences
Summary
Food intake was reduced by exenatide, pramlintide acetate, and [D-Leu-4]-OB3 alone, and co-delivery with [D-Leu-4]-OB3 did not induce a further decrease.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
Report a problemFND-2296040305
04AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, pramlintide acetate alone reduced food intake.
In plain wordsIn mice, pramlintide acetate alone reduced food intake.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseFood intake
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · oral gavage · 14 daysAs given in this study (mouse).
Source sentences
Summary
Food intake was reduced by exenatide, pramlintide acetate, and [D-Leu-4]-OB3 alone, and co-delivery with [D-Leu-4]-OB3 did not induce a further decrease.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
Report a problemFND-2296040306
05AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, exenatide alone did not affect water intake.
In plain wordsIn mice, exenatide alone did not affect water intake.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeWater intake
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · oral gavage · 14 daysAs given in this study (mouse).
Source sentences
Summary
Water intake was not affected by exenatide, pramlintide acetate, or [D-Leu-4]-OB3 alone, but co-delivery of exenatide or pramlintide acetate with [D-Leu-4]-OB3 resulted in a significant reduction in water intake.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
Report a problemFND-2296040309
06AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, pramlintide acetate alone did not affect water intake.
In plain wordsIn mice, pramlintide acetate alone did not affect water intake.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeWater intake
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · oral gavage · 14 daysAs given in this study (mouse).
Source sentences
Summary
Water intake was not affected by exenatide, pramlintide acetate, or [D-Leu-4]-OB3 alone, but co-delivery of exenatide or pramlintide acetate with [D-Leu-4]-OB3 resulted in a significant reduction in water intake.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
Report a problemFND-2296040310
07AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, oral exenatide lowered blood glucose.
In plain wordsIn mice, oral exenatide lowered blood glucose.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBlood glucose
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral gavage · 14 daysAs given in this study (mouse).
Measurements
Blood glucose reduction
20.4%
exenatide
Source sentences
Summary
Oral delivery of exenatide or pramlintide acetate in DDM significantly lowered blood glucose levels by 20.4% and 30.2%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
Report a problemFND-2296040313
08AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, oral pramlintide acetate lowered blood glucose.
In plain wordsIn mice, oral pramlintide acetate lowered blood glucose.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBlood glucose
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral gavage · 14 daysAs given in this study (mouse).
Measurements
Blood glucose reduction
30.2%
pramlintide acetate
Source sentences
Summary
Oral delivery of exenatide or pramlintide acetate in DDM significantly lowered blood glucose levels by 20.4% and 30.2%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
Report a problemFND-2296040314
09AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, increasing exenatide concentrations increased serum insulin.
In plain wordsIn mice, higher exenatide concentrations increased serum insulin.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSerum insulin concentration response
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral gavage · 14 daysAs given in this study (mouse).
Source sentences
Summary
A concentration-dependent increase in serum insulin was observed in response to increasing concentrations of exenatide, and [D-Leu-4]-OB3 slightly reduced the insulin response to exenatide at all concentrations tested.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
Report a problemFND-2296040317
10AnimalAnimal study (in vivo)Efficacy outcome
In diabetic mice, increasing pramlintide acetate concentrations did not elevate serum insulin.
In plain wordsIn mice, higher pramlintide acetate concentrations did not increase serum insulin.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeSerum insulin concentration response
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oral gavage · 14 daysAs given in this study (mouse).
Source sentences
Summary
Increasing concentrations of pramlintide acetate alone did not elevate serum insulin, and when given in combination with [D-Leu-4]-OB3, serum insulin levels fell below those of DDM-treated control mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
Report a problemFND-2296040319

Studies that did not test the peptide alone10

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

11AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, exenatide with [D-Leu-4]-OB3 reduced weight from baseline.
In plain wordsIn mice, exenatide with [D-Leu-4]-OB3 reduced weight from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight change with combination
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
4.2%
combination
Source sentences
Summary
Mice receiving exenatide and [D-Leu-4]-OB3 were 4.2% lighter than they were at the beginning of the study.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2296040302
12AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, adding [D-Leu-4]-OB3 to pramlintide acetate did not further reduce weight gain.
In plain wordsIn mice, pramlintide acetate with [D-Leu-4]-OB3 did not reduce weight gain further than pramlintide alone.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeBody weight gain with combination
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Comparator
pramlintide acetate alone
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Co-administration of pramlintide acetate and [D-Leu-4]-OB3 did not further enhance the effect of pramlintide acetate on body weight gain.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2296040304
13AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, adding [D-Leu-4]-OB3 to exenatide did not further reduce food intake.
In plain wordsIn mice, exenatide with [D-Leu-4]-OB3 did not reduce food intake further than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeFood intake with combination
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Comparator
exenatide alone
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Food intake was reduced by exenatide, pramlintide acetate, and [D-Leu-4]-OB3 alone, and co-delivery with [D-Leu-4]-OB3 did not induce a further decrease.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2296040307
14AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, adding [D-Leu-4]-OB3 to pramlintide acetate did not further reduce food intake.
In plain wordsIn mice, pramlintide with [D-Leu-4]-OB3 did not reduce food intake further than pramlintide alone.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeFood intake with combination
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Comparator
pramlintide acetate alone
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Food intake was reduced by exenatide, pramlintide acetate, and [D-Leu-4]-OB3 alone, and co-delivery with [D-Leu-4]-OB3 did not induce a further decrease.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2296040308
15AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, exenatide with [D-Leu-4]-OB3 reduced water intake.
In plain wordsIn mice, exenatide with [D-Leu-4]-OB3 reduced water intake.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWater intake with combination
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Water intake was not affected by exenatide, pramlintide acetate, or [D-Leu-4]-OB3 alone, but co-delivery of exenatide or pramlintide acetate with [D-Leu-4]-OB3 resulted in a significant reduction in water intake.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2296040311
16AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, pramlintide acetate with [D-Leu-4]-OB3 reduced water intake.
In plain wordsIn mice, pramlintide acetate with [D-Leu-4]-OB3 reduced water intake.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseWater intake with combination
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Water intake was not affected by exenatide, pramlintide acetate, or [D-Leu-4]-OB3 alone, but co-delivery of exenatide or pramlintide acetate with [D-Leu-4]-OB3 resulted in a significant reduction in water intake.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2296040312
17AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, exenatide with [D-Leu-4]-OB3 further reduced blood glucose versus exenatide alone.
In plain wordsIn mice, exenatide with [D-Leu-4]-OB3 reduced glucose further than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBlood glucose with combination
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Comparator
exenatide alone
Outcome group
Glycemic control · Metabolic and weight
Measurements
Blood glucose reduction
38.3%
co-delivery
Source sentences
Summary
Co-delivery with [D-Leu-4]-OB3 further reduced blood glucose by 38.3% and 50.5%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Oral delivery of exenatide or pramlintide acetate in DDM significantly lowered blood glucose levels by 20.4% and 30.2%, respectively.
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2296040315
18AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, pramlintide acetate with [D-Leu-4]-OB3 further reduced blood glucose versus pramlintide acetate alone.
In plain wordsIn mice, pramlintide with [D-Leu-4]-OB3 reduced glucose further than pramlintide alone.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBlood glucose with combination
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Comparator
pramlintide acetate alone
Outcome group
Glycemic control · Metabolic and weight
Measurements
Blood glucose reduction
50.5%
co-delivery
Source sentences
Summary
Co-delivery with [D-Leu-4]-OB3 further reduced blood glucose by 38.3% and 50.5%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Oral delivery of exenatide or pramlintide acetate in DDM significantly lowered blood glucose levels by 20.4% and 30.2%, respectively.
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2296040316
19AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, adding [D-Leu-4]-OB3 slightly reduced the insulin response to exenatide.
In plain wordsIn mice, exenatide with [D-Leu-4]-OB3 produced a slightly lower insulin response than exenatide alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSerum insulin with combination
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Comparator
exenatide alone
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
A concentration-dependent increase in serum insulin was observed in response to increasing concentrations of exenatide, and [D-Leu-4]-OB3 slightly reduced the insulin response to exenatide at all concentrations tested.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2296040318
20AnimalNot a test of Pramlintide (Symlin) aloneAnimal study (in vivo)Efficacy outcome
In diabetic mice, pramlintide acetate with [D-Leu-4]-OB3 lowered insulin below DDM-treated control levels.
In plain wordsIn mice, pramlintide with [D-Leu-4]-OB3 lowered insulin below DDM-treated control levels.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseSerum insulin with combination
Study
mousen: not reported in source
insulin-resistant male C57BLK/6-m db/db mice
Comparator
DDM-treated controls
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Increasing concentrations of pramlintide acetate alone did not elevate serum insulin, and when given in combination with [D-Leu-4]-OB3, serum insulin levels fell below those of DDM-treated control mice.
1 context sentence(design, population, supporting numbers)
Summary · context
Exenatide or pramlintide acetate was reconstituted in dodecyl maltoside (DDM) in the absence or presence of [D-Leu-4]-OB3, and delivered orally by gavage to insulin-resistant male C57BLK/6-m db/db mice twice daily for 14 days.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2296040320

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.